Xuewen Wu
Agnieszka J. Szczepek
Hajime Sano
Yong Feng- 1Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China
- 2Department of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
- 3Department of Rehabilitation, Kitasato University Faculty of Allied Health Sciences, Kanagawa, Japan
- 4Department of Otorhinolaryngology, University of South China Affiliated Changsha Central Hospital, Changsha, Hunan, China
Editorial on the Research Topic
Etiological mechanisms and treatments of idiopathic sudden sensorineural hearing loss
As a common otological emergency, idiopathic sudden sensorineural hearing loss (ISSNHL) occurs suddenly and without any prior warning, and is defined as hearing loss of at least 30 dB in three sequential frequencies within 72 h. The incidence of ISSNHL in Western countries was estimated to be 5–20 per 100,000 population (1). More recent investigations showed the annual incidence of ISSNHL to be 60.9 per 100,000 in Japan and 2.4–19 per 100,000 in some provinces of China, respectively (2–4). ISSNHL can be caused by a variety of factors, including vascular disorders, viral infections, and autoimmune diseases. However, the etiology and exact pathophysiology remain unclear in most cases, making the development of effective treatments challenging. This Research Topic aimed to gather recent findings that elaborate on the advanced etiological mechanisms and treatments of ISSNHL.
According to clinical practice, 3D-FLAIR magnetic resonance imaging (MRI) evaluation is an option for evaluating inner ear disturbances. It was reported that high signals can be found in the inner ear on 3D-FLAIR MRI in ISSNHL patients (5). In this Research Topic, Sone et al. review related clinical articles focusing on high signal and endolymphatic hydrops (EH) in the inner ear and describe the proposed pathophysiology of ISSNHL using cutting-edge 3D-FLAIR MRI evaluation. They find that different high signals on 3D-FLAIR MRI at different times represent different pathological patterns of the inner ear. For example, a pre-contrast high signal may indicate minor hemorrhage or increased permeability of surrounding vessels to the perilymph, whereas a post-contrast high signal indicates a breakdown of the blood–labyrinth barrier. In addition, primary EH could be pre-existing in some cases and may be a risk factor for the onset of ISSNHL. The authors suggest that the cutting-edge 3D-FLAIR MRI could be adopted as an evaluation method for elucidating the pathophysiology and predicting prognosis in ISSNHL.
Although the most frequently used treatment for ISSNHL is the administration of steroids (6, 7), other various empirical treatments also have been applied by some doctors in many countries, including hyperbaric oxygen therapy (HBOT), vasodilators, defibrinogen, and anticoagulant agents. Over the last two decades, HBOT and intratympanic steroids (ITS) were proposed as salvage treatments in cases of failure of systemic steroids (8, 9). Although HBOT and ITS have been proposed as optional treatments for ISSNHL patients in Europe and the United States more recently (10–13), there is still no broad, unanimous consensus about the efficacy of these treatments. In this Research Topic, Skarzynski et al. perform a retrospective study to comparatively investigate the efficacy of HBOT as an adjunct to glucocorticoid treatment in 63 adult ISSNHL patients. In this study, they do not find a beneficial effect of HBOT for ISSNHL. Mariani et al. perform a retrospective study on 75 ISSNHL patients to investigate the efficacy of HBOT and ITS in addition to systemic steroids. They find that the salvage treatments, both HBOT and ITS associated with systemic steroids, have similar hearing outcomes with no statistical differences as consecutive systemic steroids. These two articles indicate that HBOT or ITS may be of little benefit as salvage treatments.
Defibrinogen therapy for ISSNHL is also controversial. Some studies have indicated that intravenous batroxobin, a kind of defibrinogen medicine, may be effective in treating patients with ISSNHL (14, 15). The reduction of fibrinogen was presented as one of the main treatments for ISSNHL in the German Guideline (16, 17). Intravenous batroxobin was also recommended in the treatment of flat-type and total-deafness ISSNHL in the Chinese Guideline (18, 19). However, defibrinogen therapy was strongly recommended against for ISSNHL patients in the American Practice Guideline (1). In this Research Topic, Jiang et al. conduct a retrospective propensity score-matched study on 162 ISSNHL patients to investigate whether treatment combined with intravenous batroxobin is better than treatment without batroxobin. They find that there is no significant difference in short-term hearing outcomes between treatment with batroxobin and treatment without batroxobin in ISSNHL patients. Thus, the efficacy of batroxobin for the treatment of ISSNHL still remains to be determined.
In general, the etiology and exact pathophysiology of ISSNHL remain unclear, and the development of standardized treatments is also hampered. The efficacy of HBOT and ITS as salvage treatments and the long-term efficacy of batroxobin still need to be confirmed with larger randomized controlled trials. As research continues to uncover the underlying causes of ISSNHL, it may be possible to develop more targeted and effective treatments for ISSNHL.
Author contributions
XW: Writing—original draft, Writing—review and editing. AS: Writing—review and editing. HS: Writing—review and editing. YF: Writing—review and editing.
Funding
This work was supported by grants to XW from National Natural Science Foundation of China (82371169) and research project on postgraduate Education and Teaching Reform of Central South University (2023JGB115).
Acknowledgments
We would like to express our deepest gratitude to the reviewers whose professional comments guaranteed the high quality of the selected articles. In addition, we also would like to express our appreciation to the editorial board members and publishing office of the journal for their help and support throughout the preparation of this Research Topic.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Stachler RJ, Chandrasekhar SS, Archer SM, Rosenfeld RM, Schwartz SR, Barrs DM, et al. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg. (2012) 146:S1–35. doi: 10.1177/0194599812436449
2. Nakashima T, Sato H, Gyo K, Hato N, Yoshida T, Shimono M, et al. Idiopathic sudden sensorineural hearing loss in Japan. Acta Otolaryngol. (2014) 134:1158–63. doi: 10.3109/00016489.2014.919406
3. Zhang X, Xu X, Ma W, Zhang Q, Tong B, Yu H, et al. A clinical study of sudden deafness. Acta Otolaryngol. (2015) 135:1030–5. doi: 10.3109/00016489.2015.1060629
4. Xie W, Dai Q, Liu J, Liu Y, Hellström S, Duan M, et al. Analysis of clinical and laboratory findings of idiopathic sudden sensorineural hearing loss. Sci Rep. (2020) 10:6057. doi: 10.1038/s41598-020-63046-z
5. Sugiura M, Naganawa S, Teranishi M, Nakashima T. Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging findings in patients with sudden sensorineural hearing loss. Laryngoscope. (2006) 116:1451–4. doi: 10.1097/01.mlg.0000228005.78187.23
6. Schreiber BE, Agrup C, Haskard DO, Luxon LM. Sudden sensorineural hearing loss. Lancet. (2010) 375:1203–11. doi: 10.1016/S0140-6736(09)62071-7
7. Wei BP, Stathopoulos D, O'Leary S. Steroids for idiopathic sudden sensorineural hearing loss. Cochrane Database Syst Rev. (2013) 7:CD003998. doi: 10.1002/14651858.CD003998.pub3
8. Joshua TG, Ayub A, Wijesinghe P, Nunez DA. Hyperbaric oxygen therapy for patients with sudden sensorineural hearing loss: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. (2022) 148:5–11. doi: 10.1001/jamaoto.2021.2685
9. Plontke SK, Meisner C, Agrawal S, Cayé-Thomasen P, Galbraith K, Mikulec AA, et al. Intratympanic corticosteroids for sudden sensorineural hearing loss. Cochrane Database Syst Rev. (2022) 7:CD008080. doi: 10.1002/14651858.CD008080.pub2
10. Marx M, Younes E, Chandrasekhar SS, Ito J, Plontke S, O'Leary S, et al. International consensus (ICON) on treatment of sudden sensorineural hearing loss. Eur Ann Otorhinolaryngol Head Neck Dis. (2018) 135(1S):S23–8. doi: 10.1016/j.anorl.2017.12.011
11. Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. (2017) 47:24–32. doi: 10.28920/dhm47.2.131-132
12. Herrera M, García Berrocal JR, García Arumí A, Lavilla MJ, Plaza G, Grupo de Trabajo de la Comisión de Audiología de la SEORL. Update on consensus on diagnosis and treatment of idiopathic sudden sensorineural hearing loss. Actualización del consenso sobre el diagnóstico y tratamiento de la sordera súbita idiopática. Acta Otorrinolaringol Esp. (2019) 70:290–300. doi: 10.1016/j.otorri.2018.04.010
13. Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA, et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg. (2019) 161(1_suppl):S1–45. doi: 10.1177/0194599819859885
14. Oya R, Horii A, Akazawa H, Osaki Y, Inohara H. Prognostic predictors of sudden sensorineural hearing loss in defibrinogenation therapy. Acta Otolaryngol. (2016) 136:271–6. doi: 10.3109/00016489.2015.1104723
15. Jia H, Yu Z, Li X, Wang J, Ge X, Chen Z-T, et al. Efficacy of intratympanic corticosteroid, intravenous batroxobin and combined treatment for sudden sensorineural hearing loss with type-2 diabetes. Acta Otolaryngol. (2019) 139:522–8. doi: 10.1080/00016489.2019.1592221
17. Michel O, Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopfund Hals-Chirurgie. Die aktuell gefasste Leitlinie “Hörsturz” (Akuter idiopathischer sensorineuraler Hörverlust) [The revised version of the german guidelines “sudden idiopathic sensorineural hearing loss”]. Laryngorhinootologie. (2011) 90:290–3. doi: 10.1055/s-0031-1273721
19. Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Society of Otorhinolaryngology Head and Neck Surgery Chinese Medical Association. Guideline of diagnosis and treatment of sudden deafness. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. (2015) 50:443–7. doi: 10.3760/cma.j.issn.1673-0860.2015.06.002
Keywords: idiopathic sudden sensorineural hearing loss, hyperbaric oxygen therapy, steroids, magnetic resonance imaging, batroxobin
Citation: Wu X, Szczepek AJ, Sano H and Feng Y (2023) Editorial: Etiological mechanisms and treatments of idiopathic sudden sensorineural hearing loss. Front. Neurol. 14:1292836. doi: 10.3389/fneur.2023.1292836
Received: 12 September 2023; Accepted: 14 September 2023;
Published: 28 September 2023.
Edited and reviewed by: Michael Strupp, Ludwig Maximilian University of Munich, Germany
Copyright © 2023 Wu, Szczepek, Sano and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xuewen Wu, xwwu840903@hotmail.com